ZA200606409B - Pharmaceutical compositions comprising a proton pump inhibitor and a prokinetic - Google Patents

Pharmaceutical compositions comprising a proton pump inhibitor and a prokinetic Download PDF

Info

Publication number: ZA200606409B
Authority: ZA; South Africa
Prior art keywords: agent; composition according; prokinetic agent; release form; pharmaceutically acceptable
Prior art date: 2004-01-06

Application number

ZA200606409A

Other languages

English (en)

Inventor

Rajesh Jain

Kour Chand Jindal

Sukhjeet Singh

Original Assignee

Panacea Biotec Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-01-06

Filing date

2005-01-05

Publication date

2008-06-25

2005-01-05 Application filed by Panacea Biotec Ltd filed Critical Panacea Biotec Ltd

2008-06-25 Publication of ZA200606409B publication Critical patent/ZA200606409B/en

Links

229940126409 proton pump inhibitor Drugs 0.000 title claims description 19
239000000612 proton pump inhibitor Substances 0.000 title claims description 19
239000008194 pharmaceutical composition Substances 0.000 title claims description 14
239000002325 prokinetic agent Substances 0.000 claims description 87
239000000203 mixture Substances 0.000 claims description 70
239000003826 tablet Substances 0.000 claims description 70
239000003795 chemical substances by application Substances 0.000 claims description 41
230000003111 delayed effect Effects 0.000 claims description 39
229960001253 domperidone Drugs 0.000 claims description 35
FGXWKSZFVQUSTL-UHFFFAOYSA-N domperidone Chemical compound C12=CC=CC=C2NC(=O)N1CCCN(CC1)CCC1N1C2=CC=C(Cl)C=C2NC1=O FGXWKSZFVQUSTL-UHFFFAOYSA-N 0.000 claims description 35
210000004211 gastric acid Anatomy 0.000 claims description 32
238000004519 manufacturing process Methods 0.000 claims description 25
239000000546 pharmaceutical excipient Substances 0.000 claims description 25
IQPSEEYGBUAQFF-UHFFFAOYSA-N Pantoprazole Chemical compound COC1=CC=NC(CS(=O)C=2NC3=CC=C(OC(F)F)C=C3N=2)=C1OC IQPSEEYGBUAQFF-UHFFFAOYSA-N 0.000 claims description 24
239000012729 immediate-release (IR) formulation Substances 0.000 claims description 24
229960005019 pantoprazole Drugs 0.000 claims description 24
150000002148 esters Chemical class 0.000 claims description 19
150000004677 hydrates Chemical class 0.000 claims description 19
150000003839 salts Chemical class 0.000 claims description 19
239000002662 enteric coated tablet Substances 0.000 claims description 15
208000021302 gastroesophageal reflux disease Diseases 0.000 claims description 15
GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 14
229960004503 metoclopramide Drugs 0.000 claims description 14
TTWJBBZEZQICBI-UHFFFAOYSA-N metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 claims description 14
230000002902 bimodal effect Effects 0.000 claims description 12
SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 claims description 11
239000002253 acid Substances 0.000 claims description 11
229960000381 omeprazole Drugs 0.000 claims description 11
239000012730 sustained-release form Substances 0.000 claims description 11
QQQIECGTIMUVDS-UHFFFAOYSA-N N-[[4-[2-(dimethylamino)ethoxy]phenyl]methyl]-3,4-dimethoxybenzamide Chemical compound C1=C(OC)C(OC)=CC=C1C(=O)NCC1=CC=C(OCCN(C)C)C=C1 QQQIECGTIMUVDS-UHFFFAOYSA-N 0.000 claims description 10
239000007903 gelatin capsule Substances 0.000 claims description 10
229960005302 itopride Drugs 0.000 claims description 10
238000011068 loading method Methods 0.000 claims description 10
150000007524 organic acids Chemical class 0.000 claims description 10
229920000642 polymer Polymers 0.000 claims description 10
239000007941 film coated tablet Substances 0.000 claims description 8
239000008187 granular material Substances 0.000 claims description 8
238000000034 method Methods 0.000 claims description 8
239000000651 prodrug Substances 0.000 claims description 8
229940002612 prodrug Drugs 0.000 claims description 8
238000011282 treatment Methods 0.000 claims description 8
208000007107 Stomach Ulcer Diseases 0.000 claims description 7
229930003427 Vitamin E Natural products 0.000 claims description 7
POODVSCQKVCWCE-UHFFFAOYSA-N butanedioic acid;propane-1,2-diol Chemical compound CC(O)CO.OC(=O)CCC(O)=O POODVSCQKVCWCE-UHFFFAOYSA-N 0.000 claims description 7
WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 7
201000005917 gastric ulcer Diseases 0.000 claims description 7
229960004157 rabeprazole Drugs 0.000 claims description 7
YREYEVIYCVEVJK-UHFFFAOYSA-N rabeprazole Chemical compound COCCCOC1=CC=NC(CS(=O)C=2NC3=CC=CC=C3N=2)=C1C YREYEVIYCVEVJK-UHFFFAOYSA-N 0.000 claims description 7
235000019165 vitamin E Nutrition 0.000 claims description 7
229940046009 vitamin E Drugs 0.000 claims description 7
239000011709 vitamin E Substances 0.000 claims description 7
ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 claims description 6
ZAKOWWREFLAJOT-ADUHFSDSSA-N [2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-3,4-dihydrochromen-6-yl] acetate Chemical group CC(=O)OC1=C(C)C(C)=C2OC(CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-ADUHFSDSSA-N 0.000 claims description 6
239000011248 coating agent Substances 0.000 claims description 6
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
208000035475 disorder Diseases 0.000 claims description 6
239000002552 dosage form Substances 0.000 claims description 6
239000000463 material Substances 0.000 claims description 6
229960005132 cisapride Drugs 0.000 claims description 5
DCSUBABJRXZOMT-IRLDBZIGSA-N cisapride Chemical compound C([C@@H]([C@@H](CC1)NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)OC)N1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-IRLDBZIGSA-N 0.000 claims description 5
DCSUBABJRXZOMT-UHFFFAOYSA-N cisapride Natural products C1CC(NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)C(OC)CN1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-UHFFFAOYSA-N 0.000 claims description 5
239000003961 penetration enhancing agent Substances 0.000 claims description 5
208000008469 Peptic Ulcer Diseases 0.000 claims description 4
239000007931 coated granule Substances 0.000 claims description 4
239000003085 diluting agent Substances 0.000 claims description 4
239000007884 disintegrant Substances 0.000 claims description 4
239000003814 drug Substances 0.000 claims description 4
229960003174 lansoprazole Drugs 0.000 claims description 4
MJIHNNLFOKEZEW-UHFFFAOYSA-N lansoprazole Chemical compound CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1 MJIHNNLFOKEZEW-UHFFFAOYSA-N 0.000 claims description 4
239000000314 lubricant Substances 0.000 claims description 4
239000008203 oral pharmaceutical composition Substances 0.000 claims description 4
208000000689 peptic esophagitis Diseases 0.000 claims description 4
208000011906 peptic ulcer disease Diseases 0.000 claims description 4
238000002360 preparation method Methods 0.000 claims description 4
DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 claims description 3
FEROPKNOYKURCJ-UHFFFAOYSA-N 4-amino-N-(1-azabicyclo[2.2.2]octan-3-yl)-5-chloro-2-methoxybenzamide Chemical compound COC1=CC(N)=C(Cl)C=C1C(=O)NC1C(CC2)CCN2C1 FEROPKNOYKURCJ-UHFFFAOYSA-N 0.000 claims description 3
108010016076 Octreotide Proteins 0.000 claims description 3
239000003963 antioxidant agent Substances 0.000 claims description 3
235000006708 antioxidants Nutrition 0.000 claims description 3
NZUPCNDJBJXXRF-UHFFFAOYSA-O bethanechol Chemical compound C[N+](C)(C)CC(C)OC(N)=O NZUPCNDJBJXXRF-UHFFFAOYSA-O 0.000 claims description 3
229960000910 bethanechol Drugs 0.000 claims description 3
239000011230 binding agent Substances 0.000 claims description 3
238000000576 coating method Methods 0.000 claims description 3
239000003086 colorant Substances 0.000 claims description 3
229960003276 erythromycin Drugs 0.000 claims description 3
229960004770 esomeprazole Drugs 0.000 claims description 3
SUBDBMMJDZJVOS-DEOSSOPVSA-N esomeprazole Chemical compound C([S@](=O)C1=NC2=CC=C(C=C2N1)OC)C1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-DEOSSOPVSA-N 0.000 claims description 3
UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 claims description 3
229960004127 naloxone Drugs 0.000 claims description 3
229960002700 octreotide Drugs 0.000 claims description 3
239000003605 opacifier Substances 0.000 claims description 3
239000004014 plasticizer Substances 0.000 claims description 3
GZSKEXSLDPEFPT-IINYFYTJSA-N renzapride Chemical compound COC1=CC(N)=C(Cl)C=C1C(=O)N[C@H]1[C@H](C2)CCC[N@]2CC1 GZSKEXSLDPEFPT-IINYFYTJSA-N 0.000 claims description 3
229950003039 renzapride Drugs 0.000 claims description 3
229950004681 zacopride Drugs 0.000 claims description 3
238000011049 filling Methods 0.000 claims description 2
230000002459 sustained effect Effects 0.000 claims 1
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 63
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 38
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 36
239000000454 talc Substances 0.000 description 31
229910052623 talc Inorganic materials 0.000 description 31
229940033134 talc Drugs 0.000 description 31
235000012222 talc Nutrition 0.000 description 31
235000019359 magnesium stearate Nutrition 0.000 description 19
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 18
229920002785 Croscarmellose sodium Polymers 0.000 description 17
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 17
229960001681 croscarmellose sodium Drugs 0.000 description 17
235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 17
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 13
239000004615 ingredient Substances 0.000 description 13
239000008101 lactose Substances 0.000 description 13
229960001375 lactose Drugs 0.000 description 13
239000008199 coating composition Substances 0.000 description 12
229920003139 Eudragit® L 100 Polymers 0.000 description 9
229920003135 Eudragit® L 100-55 Polymers 0.000 description 9
229920000168 Microcrystalline cellulose Polymers 0.000 description 9
239000002702 enteric coating Substances 0.000 description 9
238000009505 enteric coating Methods 0.000 description 9
239000008108 microcrystalline cellulose Substances 0.000 description 9
229940016286 microcrystalline cellulose Drugs 0.000 description 9
235000019813 microcrystalline cellulose Nutrition 0.000 description 9
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
239000002775 capsule Substances 0.000 description 8
238000004090 dissolution Methods 0.000 description 8
DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 7
CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 7
235000013539 calcium stearate Nutrition 0.000 description 7
239000008116 calcium stearate Substances 0.000 description 7
239000001069 triethyl citrate Substances 0.000 description 7
VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 7
235000013769 triethyl citrate Nutrition 0.000 description 7
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 5
229930195725 Mannitol Natural products 0.000 description 5
238000002648 combination therapy Methods 0.000 description 5
GDCRSXZBSIRSFR-UHFFFAOYSA-N ethyl prop-2-enoate;2-methylprop-2-enoic acid Chemical compound CC(=C)C(O)=O.CCOC(=O)C=C GDCRSXZBSIRSFR-UHFFFAOYSA-N 0.000 description 5
239000000594 mannitol Substances 0.000 description 5
235000010355 mannitol Nutrition 0.000 description 5
239000008213 purified water Substances 0.000 description 5
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
239000000872 buffer Substances 0.000 description 4
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 4
229940057948 magnesium stearate Drugs 0.000 description 4
239000002002 slurry Substances 0.000 description 4
-1 Avicel® PH 101 Polymers 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
150000001875 compounds Chemical class 0.000 description 3
229940079593 drug Drugs 0.000 description 3
230000030135 gastric motility Effects 0.000 description 3
230000035876 healing Effects 0.000 description 3
239000000395 magnesium oxide Substances 0.000 description 3
CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 3
AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 3
239000008363 phosphate buffer Substances 0.000 description 3
238000013268 sustained release Methods 0.000 description 3
WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 2
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
229920002261 Corn starch Polymers 0.000 description 2
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
AOBORMOPSGHCAX-UHFFFAOYSA-N Tocophersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-UHFFFAOYSA-N 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
229940075614 colloidal silicon dioxide Drugs 0.000 description 2
229960000913 crospovidone Drugs 0.000 description 2
239000012738 dissolution medium Substances 0.000 description 2
230000002496 gastric effect Effects 0.000 description 2
210000001035 gastrointestinal tract Anatomy 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
239000006186 oral dosage form Substances 0.000 description 2
229940006344 pantoprazole 40 mg Drugs 0.000 description 2
229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 2
235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 2
229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 2
229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
239000001267 polyvinylpyrrolidone Substances 0.000 description 2
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 description 2
229960000620 ranitidine Drugs 0.000 description 2
229940044551 receptor antagonist Drugs 0.000 description 2
239000002464 receptor antagonist Substances 0.000 description 2
238000003756 stirring Methods 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
ZGDLVKWIZHHWIR-UHFFFAOYSA-N 4-[5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl]morpholine Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC=C(N2CCOCC2)N=C1 ZGDLVKWIZHHWIR-UHFFFAOYSA-N 0.000 description 1
YPELFRMCRYSPKZ-UHFFFAOYSA-N 4-amino-5-chloro-2-ethoxy-N-({4-[(4-fluorophenyl)methyl]morpholin-2-yl}methyl)benzamide Chemical compound CCOC1=CC(N)=C(Cl)C=C1C(=O)NCC1OCCN(CC=2C=CC(F)=CC=2)C1 YPELFRMCRYSPKZ-UHFFFAOYSA-N 0.000 description 1
LVRVABPNVHYXRT-BQWXUCBYSA-N 52906-92-0 Chemical compound C([C@H](N)C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(O)=O)C(C)C)C1=CC=CC=C1 LVRVABPNVHYXRT-BQWXUCBYSA-N 0.000 description 1
241000137586 Ambigolimax valentianus Species 0.000 description 1
229920003084 Avicel® PH-102 Polymers 0.000 description 1
GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
235000019759 Maize starch Nutrition 0.000 description 1
229920000881 Modified starch Polymers 0.000 description 1
102000002419 Motilin Human genes 0.000 description 1
101800002372 Motilin Proteins 0.000 description 1
UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
239000013543 active substance Substances 0.000 description 1
230000003542 behavioural effect Effects 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
XAAHAAMILDNBPS-UHFFFAOYSA-L calcium hydrogenphosphate dihydrate Chemical compound O.O.[Ca+2].OP([O-])([O-])=O XAAHAAMILDNBPS-UHFFFAOYSA-L 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
238000001816 cooling Methods 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
235000019700 dicalcium phosphate Nutrition 0.000 description 1
229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 1
AMTWCFIAVKBGOD-UHFFFAOYSA-N dioxosilane;methoxy-dimethyl-trimethylsilyloxysilane Chemical compound O=[Si]=O.CO[Si](C)(C)O[Si](C)(C)C AMTWCFIAVKBGOD-UHFFFAOYSA-N 0.000 description 1
230000009429 distress Effects 0.000 description 1
206010060865 duodenogastric reflux Diseases 0.000 description 1
MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
238000013265 extended release Methods 0.000 description 1
XUFQPHANEAPEMJ-UHFFFAOYSA-N famotidine Chemical group NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 description 1
229960001596 famotidine Drugs 0.000 description 1
238000009472 formulation Methods 0.000 description 1
230000005176 gastrointestinal motility Effects 0.000 description 1
239000008103 glucose Substances 0.000 description 1
229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
229960001021 lactose monohydrate Drugs 0.000 description 1
239000010410 layer Substances 0.000 description 1
239000008297 liquid dosage form Substances 0.000 description 1
229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
238000009115 maintenance therapy Methods 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
239000008185 minitablet Substances 0.000 description 1
235000019426 modified starch Nutrition 0.000 description 1
229960004085 mosapride Drugs 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
239000002245 particle Substances 0.000 description 1
230000008506 pathogenesis Effects 0.000 description 1
239000008188 pellet Substances 0.000 description 1
239000006187 pill Substances 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
230000002265 prevention Effects 0.000 description 1
229960001778 rabeprazole sodium Drugs 0.000 description 1
230000000306 recurrent effect Effects 0.000 description 1
229940083037 simethicone Drugs 0.000 description 1
238000009097 single-agent therapy Methods 0.000 description 1
229920003109 sodium starch glycolate Polymers 0.000 description 1
229940079832 sodium starch glycolate Drugs 0.000 description 1
239000008109 sodium starch glycolate Substances 0.000 description 1
229940045902 sodium stearyl fumarate Drugs 0.000 description 1
238000000935 solvent evaporation Methods 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
229940032147 starch Drugs 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

ZA200606409A 2004-01-06 2005-01-05 Pharmaceutical compositions comprising a proton pump inhibitor and a prokinetic ZA200606409B (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
IN21DE2004		2004-01-06
IN25DE2004		2004-01-06

Publications (1)

Publication Number	Publication Date
ZA200606409B true ZA200606409B (en)	2008-06-25

Family

ID=34751863

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200606409A ZA200606409B (en)	2004-01-06	2005-01-05	Pharmaceutical compositions comprising a proton pump inhibitor and a prokinetic

Country Status (11)

Country	Link
US (1)	US20070160664A1 (fr)
EP (1)	EP1729743A1 (fr)
AP (1)	AP2006003703A0 (fr)
AU (1)	AU2005204014B2 (fr)
BR (1)	BRPI0506704A (fr)
CA (1)	CA2552627A1 (fr)
EA (1)	EA012261B1 (fr)
NZ (1)	NZ548780A (fr)
RS (1)	RS20050796A (fr)
WO (1)	WO2005065664A1 (fr)
ZA (1)	ZA200606409B (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7803817B2 (en)	2005-05-11	2010-09-28	Vecta, Ltd.	Composition and methods for inhibiting gastric acid secretion
US7981908B2 (en)	2005-05-11	2011-07-19	Vecta, Ltd.	Compositions and methods for inhibiting gastric acid secretion
DK2046334T3 (da)	2006-07-25	2014-08-25	Vecta Ltd	Sammensætninger og fremgangsmåder til at hæmme mavesyresekretion ved at anvende derivater af små dicarboxylsyrer i kombination med PPI
EP2118080B1 (fr)	2007-02-09	2016-08-31	Ocera Therapeutics, Inc.	Modulateurs macrocycliques du récepteur de la ghréline et leurs procédés d'utilisation
WO2010038241A2 (fr) *	2008-09-30	2010-04-08	Panacea Biotec Limited	Compositions pharmaceutiques comprenant un inhibiteur de pompe à proton, un agent procinétique et un acide alginique
WO2011136750A1 (fr) *	2010-04-26	2011-11-03	Mahmut Bilgic	Compositions pharmaceutiques induisant un effet synergique
JPWO2012018056A1 (ja) *	2010-08-03	2013-10-03	エーザイ・アール・アンド・ディー・マネジメント株式会社	圧縮組成物
BRPI1103093A2 (pt) *	2011-06-03	2013-07-02	Eurofarma Laboratarios Ltda	composiÇço farmacÊutica oral e uso da composiÇço farmacÊutica oral
KR20130024644A (ko) *	2011-08-31	2013-03-08	한국유나이티드제약 주식회사	이토프라이드 염산염을 함유하는 제어 방출성 경구 제제의 조성물 및 그의 제조방법
JP2018518521A (ja)	2015-06-26	2018-07-12	コリアユナイテッドファーマ．インコーポレーテッド	モサプリドとラベプラゾールの複合製剤
WO2024042540A1 (fr) *	2022-08-24	2024-02-29	Alkem Laboratories Limited	Compositions de mesdopetam
WO2024224407A1 (fr) *	2023-04-28	2024-10-31	Akums Drugs & Pharmaceuticals Limited	Formulation de granulés multicouches et procédé de préparation associé

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1995001803A1 (fr) *	1993-07-06	1995-01-19	Merck & Co., Inc.	Combinaisons d'agents anti-h2 et d'agents de motilite gastro-intestinale
SE9600072D0 (sv) *	1996-01-08	1996-01-08	Astra Ab	New oral formulation of two active ingredients II
EP0951278A2 (fr) *	1997-01-03	1999-10-27	ELAN CORPORATION, Plc	Formulation de minicomprimes de cisapride a liberation prolongee
US6521255B2 (en) *	2000-01-13	2003-02-18	Osmotica Corp.	Osmotic device containing ranitidine and a prokinetic agent
EP1596838A2 (fr) *	2003-02-11	2005-11-23	Torrent Pharmaceuticals Ltd	Compositions pharmaceutiques d'administration orale une fois par jour

2005
- 2005-01-05 ZA ZA200606409A patent/ZA200606409B/en unknown
- 2005-01-05 AU AU2005204014A patent/AU2005204014B2/en not_active Ceased
- 2005-01-05 WO PCT/IN2005/000002 patent/WO2005065664A1/fr not_active Ceased
- 2005-01-05 RS YUP-2005/0796A patent/RS20050796A/sr unknown
- 2005-01-05 NZ NZ548780A patent/NZ548780A/en unknown
- 2005-01-05 BR BRPI0506704-9A patent/BRPI0506704A/pt not_active IP Right Cessation
- 2005-01-05 CA CA002552627A patent/CA2552627A1/fr not_active Abandoned
- 2005-01-05 EA EA200601286A patent/EA012261B1/ru not_active IP Right Cessation
- 2005-01-05 EP EP05709158A patent/EP1729743A1/fr not_active Withdrawn
- 2005-01-05 AP AP2006003703A patent/AP2006003703A0/xx unknown
2006
- 2006-07-06 US US11/482,186 patent/US20070160664A1/en not_active Abandoned

Also Published As

Publication number	Publication date
WO2005065664A8 (fr)	2005-10-20
CA2552627A1 (fr)	2005-07-21
AP2006003703A0 (en)	2006-08-31
EP1729743A1 (fr)	2006-12-13
WO2005065664A1 (fr)	2005-07-21
BRPI0506704A (pt)	2007-05-02
AU2005204014B2 (en)	2008-02-28
NZ548780A (en)	2008-09-26
EA200601286A1 (ru)	2007-02-27
EA012261B1 (ru)	2009-08-28
AU2005204014A1 (en)	2005-07-21
US20070160664A1 (en)	2007-07-12
RS20050796A (sr)	2007-08-03

Publication	Publication Date	Title
CA2214033C (fr)	2006-01-10	Formes galeniques par voie orale comprenant un inhibiteur de la pompe a protons et un agent pro-cinetique
FI119174B (fi)	2008-08-29	Uusi oraalinen farmaseuttinen annostelumuoto
US7029701B2 (en)	2006-04-18	Composition for the treatment and prevention of ischemic events
TWI388316B (zh)	2013-03-11	抑制胃酸分泌之組合物及方法
CZ20002314A3 (cs)	2000-11-15	Orální farmaceutická dávková forma s prodlouženým uvolňováním
WO2006011159A2 (fr)	2006-02-02	Composition pharmaceutique stabilisee contenant du sodium de rabeprazole presentant une biodisponibilite amelioree
WO2013135852A1 (fr)	2013-09-19	Formulation pharmaceutique de comprimé pour le secteur médical vétérinaire, son procédé de production et utilisation
KR20070083956A (ko)	2007-08-24	양성자 펌프 억제제를 위한 신규 변형 방출 정제 제형
AU2005204014B2 (en)	2008-02-28	Pharmaceutical compositions comprising a proton pump inhibitor and a prokinetic agent
KR102696669B1 (ko)	2024-08-20	벤즈이미다졸 유도체 화합물을 포함하는 약학적 조성물
US9370481B2 (en)	2016-06-21	Compositions and methods for inhibiting gastric acid secretion
WO2010038241A2 (fr)	2010-04-08	Compositions pharmaceutiques comprenant un inhibiteur de pompe à proton, un agent procinétique et un acide alginique
WO2017084680A1 (fr)	2017-05-26	Composition pharmaceutique contenant un médicament anti-inflammatoire non stéroïdien et un inhibiteur de pompe à protons
WO2004062552A2 (fr)	2004-07-29	Composition pharmaceutique contenant un ains et un derive benzimidazole
KR20140140353A (ko)	2014-12-09	안정성 및 약물상호작용이 개선된 경구용 복합 정제 조성물
WO2011126327A2 (fr)	2011-10-13	Composition pharmaceutique présentant des propriétés de libération contrôlée comprenant du mosapride ou de la lévodropropizine et son procédé de préparation
CA2547398A1 (fr)	2005-06-09	Compositions stables de benzimidazole a administration orale et leurs procedes de preparation
MXPA06007779A (en)	2006-12-13	Pharmaceutical compositions comprising a proton pump inhibitor and a prokinetic agent
WO2015163832A1 (fr)	2015-10-29	Composition combinée d'ibuprofène et de famotidine ayant une stabilité améliorée
HK1120421B (en)	2012-10-12	Compositions and their preparation methods for inhibiting gastric acid secretion